Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?
Chuang
Emil
E
Clinical Research, Centocor, 145 King of Prussia Road, R-4-1, Malvern, PA 19355, USA.
Del Vecchio
Alfred
A
Smolinski
Steve
S
Song
Xiao-Yu
XY
Sarisky
Robert T
RT
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000069285:Infliximab; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019562:Viral Load
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab